Shares of CareDx, Inc (NASDAQ:CDNA – Get Free Report) have received an average rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $32.00.
A number of brokerages recently issued reports on CDNA. HC Wainwright restated a “neutral” rating and issued a $26.00 price objective on shares of CareDx in a research note on Tuesday, January 14th. Stephens restated an “overweight” rating and set a $40.00 target price on shares of CareDx in a research report on Thursday. Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and cut their price target for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. StockNews.com raised CareDx from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, BTIG Research lowered their price objective on shares of CareDx from $40.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, November 5th.
View Our Latest Analysis on CareDx
Hedge Funds Weigh In On CareDx
CareDx Price Performance
Shares of CareDx stock opened at $21.06 on Tuesday. The firm has a market cap of $1.13 billion, a PE ratio of -7.80 and a beta of 1.87. CareDx has a 1 year low of $7.42 and a 1 year high of $34.84. The stock has a fifty day moving average price of $22.65 and a 200-day moving average price of $25.29.
CareDx (NASDAQ:CDNA – Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $1.46. The firm had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. As a group, equities analysts anticipate that CareDx will post -0.9 EPS for the current fiscal year.
CareDx Company Profile
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Featured Stories
- Five stocks we like better than CareDx
- What Makes a Stock a Good Dividend Stock?
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- What is a Secondary Public Offering? What Investors Need to Know
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- How to buy stock: A step-by-step guide for beginners
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.